Promakhos Therapeutics
Promakhos Therapeutics, based in Boston, MA, is a healthcare company focused on developing a platform of bacterial molecules to treat inflammatory diseases like Crohn's Disease, Type 1 Diabetes, and Multiple Sclerosis.
Company Overview
Promakhos Therapeutics, based in Boston, MA, operates in the healthcare industry, specifically within the sub-sector of therapeutics. The company specializes in developing a platform of bacterial molecules designed to control inflammation and heal. With a focus on treating Crohn's Disease, Type 1 Diabetes, and Multiple Sclerosis, Promakhos Therapeutics aims to restore the function of the immune system rather than suppressing it.
Innovative Therapeutics Platform
Promakhos Therapeutics is developing an innovative platform that uses bacterial molecules to target and control inflammation, aiding in the treatment of autoimmune diseases. Their research emphasizes healing through immune system restoration rather than suppression. This approach is focused on conditions such as Crohn's Disease, Type 1 Diabetes, and Multiple Sclerosis, aiming to offer novel therapeutic options in these areas.
Funding and Grants
The company has secured significant funding to advance its research and development efforts. Notably, Promakhos Therapeutics was awarded a $272K NIH Phase 1 SBIR grant to support the development of a new oral immunomodulating therapy for Crohn's Disease. Additionally, the company received the Propel a Cure for Crohn's Disease 2024 research award, further underscoring its commitment to advancing therapeutic solutions in this critical area.
Awards and Recognitions
Promakhos Therapeutics has been recognized for its innovative contributions to the field of therapeutics. The company was named a Life Sciences Company to Watch by Big4Bio. It was also selected as a finalist at several prestigious events, including the BIO 2023 Start-Up Stadium in Boston and the 2023 Harvard President's Innovation Challenge, highlighting its potential impact in the healthcare sector.
Industry Partnerships and Network
Promakhos Therapeutics leverages a strong network of industry partnerships and collaborations. Key partners include Metaplanet, Y Combinator, Propel a Cure, FAST, and Harvard Innovation Labs. The company's network extends to prestigious institutions such as Brigham and Women's Hospital, Broad Institute, IMBB-FORTH, MassBio, Harvard University, Dana-Farber Cancer Institute, and KU Leuven. These collaborations support the company's ongoing research and development activities.